“I would never have thought 2021 would turn out as it did,” said John Babitt, a Minneapolis-based partner with EY. He was referring to the uncharted heights achieved last year in medtech M&A deal-making and venture capital funding.
For 2021 as a whole, $111bn was paid out on 64 medtech M&A deals. Both of these were record numbers,...